A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3.
about
Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades.Cytotoxic effects of tetracycline analogues (doxycycline, minocycline and COL-3) in acute myeloid leukemia HL-60 cellsMarketed marine natural products in the pharmaceutical and cosmeceutical industries: tips for successAssociation of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia.GATA2 Inhibition Sensitizes Acute Myeloid Leukemia Cells to ChemotherapyDoes a diagnosis of myelogenous leukemia require 20% marrow myeloblasts, and does <5% marrow myeloblasts represent a remission? The history and ambiguity of arbitrary diagnostic boundaries in the understanding of myelodysplasia.Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cellsWhat Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?The role of VDR and BIM in potentiation of cytarabine-induced cell death in human AML blasts.Pre-exposure of Candida species to cytarabine and daunorubicin does not affect their in vitro antifungal susceptibility and virulence in flies.Structural basis for polymerase η-promoted resistance to the anticancer nucleoside analog cytarabine
P2860
Q30620658-80A22690-7932-4DFC-9042-86D462C00AC5Q34703798-3D20743D-57B4-438E-A841-9AA2D624300EQ35096907-EDB00391-D0A2-4E5A-9B01-8BD917498E19Q35539493-A4C631AB-E646-4893-B3DE-316632685E26Q36257547-43EF48FC-D111-47F3-8B4A-07CD436B7991Q37191355-65EFE493-D8A3-47CB-B9E1-FF51729BE370Q37376388-9D78F868-8BB1-4C45-A0BF-2306A8E6E83EQ37630747-3BACBB2B-CAB4-474D-BD72-79CFAF3F58D8Q39116969-518FE231-93BD-4289-84D4-00F97ECBE626Q39796064-F891924F-CACC-42C8-801F-660E8E375B8EQ43093543-CC1BDFB1-C88A-4C1B-86F4-7E8ADEAF3153Q58714285-05F009B5-D337-48A5-83F1-505D57821B93
P2860
A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
A historical perspective on th ...... 3 the 40th anniversary of 7+3.
@ast
A historical perspective on th ...... 3 the 40th anniversary of 7+3.
@en
A historical perspective on the development of the cytarabine
@nl
type
label
A historical perspective on th ...... 3 the 40th anniversary of 7+3.
@ast
A historical perspective on th ...... 3 the 40th anniversary of 7+3.
@en
A historical perspective on the development of the cytarabine
@nl
prefLabel
A historical perspective on th ...... 3 the 40th anniversary of 7+3.
@ast
A historical perspective on th ...... 3 the 40th anniversary of 7+3.
@en
A historical perspective on the development of the cytarabine
@nl
P1476
A historical perspective on th ...... 3 the 40th anniversary of 7+3.
@en
P2093
Marshall A Lichtman
P304
P356
10.1016/J.BCMD.2012.10.005
P577
2012-11-12T00:00:00Z